Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $6
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $9.5 to $6.
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $9.5 to $6.